BELLUS Health Inc. (BLU) Research

BELLUS Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, and founded in 1993. The firm focuses on developing therapeutic solutions for refractory chronic cough (RCC) and other related cough hypersensitivity conditions. Its leading product candidate, BLU-5937, an antagonist designed to block the P2X3 receptor, is currently progressing through Phase II clinical trials for the treatment of both RCC and chronic pruritus.

Market snapshot

Symbol
BLU
Price
$14.75
Day change
+0.03%
Market cap
$1.7B
P/E ratio
-20.86x
52-week range
6.38-14.76
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$14.75

Peer companies

  • Ambrx Biopharma Inc. (AMAM)
  • Astrana Health, Inc. (ASTH)
  • Calliditas Therapeutics AB (publ) (CALT)
  • CinCor Pharma, Inc. (CINC)
  • CTI BioPharma Corp. (CTIC)
  • DICE Therapeutics, Inc. (DICE)
  • Fusion Pharmaceuticals Inc. (FUSN)
  • Longboard Pharmaceuticals, Inc. (LBPH)

Open BELLUS Health Inc. (BLU) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.